Last reviewed · How we verify
CHF 5993 100/6/12.5 µg
CHF 5993 100/6/12.5 µg is a ICS/LABA/LAMA combination Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (potential).
CHF 5993 is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.
CHF 5993 is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (potential).
At a glance
| Generic name | CHF 5993 100/6/12.5 µg |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | ICS/LABA/LAMA combination |
| Target | Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
The formulation combines beclomethasone dipropionate (ICS) to suppress airway inflammation, formoterol (LABA) to provide rapid and sustained bronchodilation via beta-2 receptor agonism, and glycopyrronium (LAMA) to provide additional bronchodilation through muscarinic receptor antagonism. This triple therapy addresses multiple pathophysiologic mechanisms in obstructive airway disease, providing anti-inflammatory and dual bronchodilatory effects in a single inhaled device.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy (potential)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Dysphonia
Key clinical trials
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians (PHASE1)
- TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA (PHASE3)
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF 5993 100/6/12.5 µg CI brief — competitive landscape report
- CHF 5993 100/6/12.5 µg updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about CHF 5993 100/6/12.5 µg
What is CHF 5993 100/6/12.5 µg?
How does CHF 5993 100/6/12.5 µg work?
What is CHF 5993 100/6/12.5 µg used for?
Who makes CHF 5993 100/6/12.5 µg?
What drug class is CHF 5993 100/6/12.5 µg in?
What development phase is CHF 5993 100/6/12.5 µg in?
What are the side effects of CHF 5993 100/6/12.5 µg?
What does CHF 5993 100/6/12.5 µg target?
Related
- Drug class: All ICS/LABA/LAMA combination drugs
- Target: All drugs targeting Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Indication: Drugs for Asthma maintenance therapy (potential)
- Compare: CHF 5993 100/6/12.5 µg vs similar drugs
- Pricing: CHF 5993 100/6/12.5 µg cost, discount & access